Welcome, Guest. Please login or register.
August 07, 2020, 11:48:53 am

Login with username, password and session length

  • Total Members: 6232
  • Latest: jgicani
  • Total Posts: 54990
  • Total Topics: 4781
  • Online Today: 77
  • Online Ever: 1314
  • (June 22, 2016, 05:23:42 am)
Users Online
Users: 0
Guests: 59
Total: 59


Welcome to the Hep Forums, a round-the-clock discussion area for people who have Hepatitis B, C or a co-infection, their friends and family and others with questions about hepatitis and liver health. Check in frequently to read what others have to say, post your comments, and hopefully learn more about how you can reach your own health goals.

Privacy Warning: Please realize that these forums are open to all, and are fully searchable via Google and other search engines. If this concerns you, then do not use a username or avatar that are self-identifying in any way. We do not allow the deletion of anything you post in these forums, so think before you post.
  • The information shared in these forums, by moderators and members, is designed to complement, not replace, the relationship between an individual and his/her own physician.
  • All members of these forums are, by default, not considered to be licensed medical providers. If otherwise, users must clearly define themselves as such.
  • Product advertisement (including links); banners; and clinical trial, study or survey participation—is strictly prohibited by forums members unless permission has been secured from the Hep Forum Moderators.
Finished Reading This? You can collapse this or any other box on this page by clicking the symbol in each box.

Author Topic: Merck’s Hep C Drugs Show Promise for HIV Coinfection  (Read 4535 times)

0 Members and 1 Guest are viewing this topic.

Offline iana5252

  • Administrator
  • Member
  • Posts: 176
Merck’s Hep C Drugs Show Promise for HIV Coinfection
« on: March 09, 2014, 03:28:16 pm »
Promising preliminary results from a trial of Merck’s MK-5172 and MK-8742, given with or without ribavirin, showed the combination therapy was as safe in treating genotype 1 of hepatitis C virus (HCV) among those coinfected with HIV as it was among those monoinfected with hep C. The treatment appears to boast near-perfect success rates. Results from the C-WORTHY study, which is a Phase II, randomized, dose-responsive, parallel-group, multiple-site, open-label trial comparing various difficult-to-treat populations among a group of 450 people with hep C, were presented at the Conference on Retroviruses and Opportunistic Infections (CROI) in Boston.

The coinfected segment of the study included 59 people coinfected with HIV and genotype 1 of HCV who were treatment naive, did not have cirrhosis and who were taking a stable antiretroviral regimen to treat HIV.


Offline lporterrn

  • Member
  • Posts: 1,984
  • LucindaPorterRN
    • LucindaPorterRN
Re: Merck’s Hep C Drugs Show Promise for HIV Coinfection
« Reply #1 on: March 09, 2014, 03:36:24 pm »
Isn't this amazing! I thought this year's CROI provided the most reasons for optimism ever! http://www.croi2014.org/
Lucinda Porter, RN
1988 Contracted HCV
1997 Interferon nonresponder
2003 PEG + ribavirin responder-relapser
2013 Cured (Harvoni + ribavirin clinical trial)


© 2020 Smart + Strong. All Rights Reserved.   terms of use and your privacy
Smart + Strong® is a registered trademark of CDM Publishing, LLC.